{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:27:17Z","timestamp":1794637637696,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8123","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.1038\/s41586-026-10613-5","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:02:47Z","timestamp":1781103767000},"page":"780-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer"],"prefix":"10.1038","volume":"655","author":[{"given":"Xiaocui","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-3179","authenticated-orcid":false,"given":"Chunhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-7638","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-5568","authenticated-orcid":false,"given":"Fang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-7929","authenticated-orcid":false,"given":"Yanan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2866-9011","authenticated-orcid":false,"given":"Hao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5682-8738","authenticated-orcid":false,"given":"Hexiu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-7008","authenticated-orcid":false,"given":"Yong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"10613_CR1","first-page":"227","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Nature 2, 227\u2013235 (2012).","journal-title":"Nature"},{"key":"10613_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"10613_CR3","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","volume":"30","author":"S Kopetz","year":"2024","unstructured":"Kopetz, S. et al. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nat. Med. 30, 3261\u20133271 (2024).","journal-title":"Nat. Med."},{"key":"10613_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.806851","volume":"14","author":"Q Yi","year":"2022","unstructured":"Yi, Q. et al. Spectrum of BRAF aberrations and its potential clinical implications insights from integrative pan-cancer analysis. Front. Bioeng. Biotechnol. 14, 806851 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10613_CR5","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032\u20134038 (2015).","journal-title":"J. Clin. Oncol."},{"key":"10613_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol. 39, 273\u2013284 (2021).","journal-title":"J. Clin. Oncol."},{"key":"10613_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov. 8, 428\u2013443 (2018).","journal-title":"Cancer Discov."},{"key":"10613_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/PL00000854","volume":"58","author":"CM Brennan","year":"2001","unstructured":"Brennan, C. M. & Steitz, J. A. HuR and mRNA stability. Cell. Mol. Life Sci. 58, 266\u2013277 (2001).","journal-title":"Cell. Mol. Life Sci."},{"key":"10613_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2011.06.007","volume":"43","author":"N Mukherjee","year":"2011","unstructured":"Mukherjee, N. et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR (ELAVL1) couples pre-mRNA processing and mRNA stability. Mol. Cell 43, 327\u2013339 (2011).","journal-title":"Mol. Cell"},{"key":"10613_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2174\/1568009618666181031145953","volume":"19","author":"M Wu","year":"2019","unstructured":"Wu, M., Tong, C. W. S., Yan, W., To, K. K. W. & Cho, W. C. S. The RNA binding protein HuR: a promising drug target for anticancer therapy. Curr. Cancer Drug Target. 19, 382\u2013399 (2019).","journal-title":"Curr. Cancer Drug Target."},{"key":"10613_CR11","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cancers14112666","volume":"14","author":"S Lachiondo-Ortega","year":"2022","unstructured":"Lachiondo-Ortega, S. et al. Hu antigen R (HuR) protein structure, function and regulation in hepatobiliary tumors. Cancers 14, 2666 (2022).","journal-title":"Cancers"},{"key":"10613_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0161-y","volume":"31","author":"I Kotta-Loizou","year":"2014","unstructured":"Kotta-Loizou, I., Giaginis, C. & Theocharis, S. Clinical significance of HuR expression in human malignancy. Med. Oncol. 31, 161 (2014).","journal-title":"Med. Oncol."},{"key":"10613_CR13","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1074\/jbc.273.11.6417","volume":"273","author":"NS Levy","year":"1998","unstructured":"Levy, N. S., Chung, S., Furneaux, H. & Levy, A. P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273, 6417\u20136423 (1998).","journal-title":"J. Biol. Chem."},{"key":"10613_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bjc.2011.20","volume":"104","author":"T Kurosu","year":"2011","unstructured":"Kurosu, T. et al. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br. J. Cancer 104, 819\u2013829 (2011).","journal-title":"Br. J. Cancer"},{"key":"10613_CR15","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-23-0972","volume":"83","author":"JM Finan","year":"2023","unstructured":"Finan, J. M., Sutton, T. L., Dixon, D. A. & Brody, J. R. Targeting the RNA-binding protein HuR in cancer. Cancer Res. 83, 3507\u20133516 (2023).","journal-title":"Cancer Res."},{"key":"10613_CR16","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/0008-5472.CAN-15-1726","volume":"77","author":"M Lang","year":"2017","unstructured":"Lang, M. et al. HuR small-molecule inhibitor elicits differential effects in adenomatosis polyposis and colorectal carcinogenesis. Cancer Res. 77, 2424\u20132438 (2017).","journal-title":"Cancer Res."},{"key":"10613_CR17","doi-asserted-by":"publisher","first-page":"27312","DOI":"10.18632\/oncotarget.4743","volume":"6","author":"M Jimbo","year":"2015","unstructured":"Jimbo, M. et al. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget 6, 27312\u201327331 (2015).","journal-title":"Oncotarget"},{"key":"10613_CR18","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-16-2704","volume":"77","author":"SN Chand","year":"2017","unstructured":"Chand, S. N. et al. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Res. 77, 5011\u20135025 (2017).","journal-title":"Cancer Res."},{"key":"10613_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/carcin\/bgq052","volume":"31","author":"S Danilin","year":"2010","unstructured":"Danilin, S. et al. Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 31, 1018\u20131026 (2010).","journal-title":"Carcinogenesis"},{"key":"10613_CR20","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/0008-5472.CAN-15-2073","volume":"76","author":"Y-H Huang","year":"2016","unstructured":"Huang, Y.-H. et al. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res. 76, 1549\u20131559 (2016).","journal-title":"Cancer Res."},{"key":"10613_CR21","first-page":"237","volume":"26","author":"Z Yuan","year":"2011","unstructured":"Yuan, Z., Sanders, A. J., Lin Ye, Y. W. & Jiang, W. G. Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol. Rep. 26, 237\u2013245 (2011).","journal-title":"Oncol. Rep."},{"key":"10613_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.biopha.2017.04.063","volume":"91","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Huang, A., Zhang, A. & Zhou, C. HuR promotes breast cancer cell proliferation and survival via binding to CDK3 mRNA. Biomed. Pharmacother. 91, 788\u2013795 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"10613_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biomedicines9020119","volume":"9","author":"V Papatheofani","year":"2021","unstructured":"Papatheofani, V. et al. HuR protein in hepatocellular carcinoma: implications in development, prognosis and treatment. Biomedicines 9, 119 (2021).","journal-title":"Biomedicines"},{"key":"10613_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10529-018-2512-9","volume":"40","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y., Yang, L., Ling, C. & Heng, W. HuR facilitates cancer stemness of lung cancer cells via regulating miR-873\/CDK3 and miR-125a-3p\/CDK3 axis. Biotechnol. Lett. 40, 623\u2013631 (2018).","journal-title":"Biotechnol. Lett."},{"key":"10613_CR25","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1172\/JCI130379","volume":"130","author":"M Palomo-Irigoyen","year":"2020","unstructured":"Palomo-Irigoyen, M. et al. HuR\/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. J. Clin. Invest. 130, 3848\u20133864 (2020).","journal-title":"J. Clin. Invest."},{"key":"10613_CR26","doi-asserted-by":"publisher","first-page":"e1581","DOI":"10.1002\/wrna.1581","volume":"11","author":"CW Schultz","year":"2020","unstructured":"Schultz, C. W., Preet, R., Dhir, T., Dixon, D. A. & Brody, J. R. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). WIREs RNA 11, e1581 (2020).","journal-title":"WIREs RNA"},{"key":"10613_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"10613_CR28","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2021014701","volume":"139","author":"W Wu","year":"2022","unstructured":"Wu, W. et al. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood 139, 2024\u20132037 (2022).","journal-title":"Blood"},{"key":"10613_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/2643-3230.BCD-20-0105","volume":"2","author":"A Renneville","year":"2021","unstructured":"Renneville, A. et al. Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood Cancer Discov. 2, 250\u2013265 (2021).","journal-title":"Blood Cancer Discov."},{"key":"10613_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"10613_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.chembiol.2023.02.005","volume":"30","author":"S Bonazzi","year":"2023","unstructured":"Bonazzi, S. et al. Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem. Biol. 30, 235\u2013247.e12 (2023).","journal-title":"Cell Chem. Biol."},{"key":"10613_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.adk6129","volume":"385","author":"PY Ting","year":"2024","unstructured":"Ting, P. Y. et al. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Science 385, 91\u201399 (2024).","journal-title":"Science"},{"key":"10613_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"10613_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"10613_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela, M. E. et al. Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex. Nat. Struct. Mol. Biol. 27, 319\u2013322 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10613_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"10613_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thom\u00e4, N. H. Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"10613_CR38","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41594-022-00849-w","volume":"29","author":"M Akdel","year":"2022","unstructured":"Akdel, M. et al. A structural biology community assessment of AlphaFold2 applications. Nat. Struct. Mol. Biol. 29, 1056\u20131067 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10613_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/nar\/gkr783","volume":"40","author":"W Dai","year":"2012","unstructured":"Dai, W., Zhang, G. & Makeyev, E. V. RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Res. 40, 787\u2013800 (2012).","journal-title":"Nucleic Acids Res."},{"key":"10613_CR40","doi-asserted-by":"crossref","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","DOI":"10.1126\/science.aat0572"},{"key":"10613_CR41","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"10613_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549\u2013553 (2022).","journal-title":"Science"},{"key":"10613_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","volume":"583","author":"F Abascal","year":"2020","unstructured":"Abascal, F. et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583, 699\u2013710 (2020).","journal-title":"Nature"},{"key":"10613_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0645-4","volume":"16","author":"A Marranci","year":"2017","unstructured":"Marranci, A. et al. The landscape of BRAF transcript and protein variants in human cancer. Mol. Cancer 16, 85 (2017).","journal-title":"Mol. Cancer"},{"key":"10613_CR45","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1074\/jbc.M112.423871","volume":"288","author":"S-H Chang","year":"2013","unstructured":"Chang, S.-H. et al. Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. J. Biol. Chem. 288, 4908\u20134921 (2013).","journal-title":"J. Biol. Chem."},{"key":"10613_CR46","unstructured":"Benson, A. B. et al. Colon Cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl Comp. Cancer Netw. 22, e240029 (2024)."},{"key":"10613_CR47","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz, S. et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat. Med. 31, 901\u2013908 (2025).","journal-title":"Nat. Med."},{"key":"10613_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-019-1331-9","volume":"10","author":"A Wang","year":"2019","unstructured":"Wang, A. et al. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer. Cell Death Dis. 10, 154 (2019).","journal-title":"Cell Death Dis."},{"key":"10613_CR49","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1021\/jacsau.5c00551","volume":"5","author":"L Kassabri","year":"2025","unstructured":"Kassabri, L. & Benhamou, R. I. Druglike molecular degraders of the oncogenic RNA-binding protein HuR. JACS Au 5, 3879\u20133891 (2025).","journal-title":"JACS Au"},{"key":"10613_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42546-2","volume":"14","author":"A Fletcher","year":"2023","unstructured":"Fletcher, A. et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat. Commun. 14, 7093 (2023).","journal-title":"Nat. Commun."},{"key":"10613_CR51","doi-asserted-by":"crossref","unstructured":"Benoit, R. M. et al. The X-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. J. Mol. Biol. 397, 1231\u20131244 (2010).","DOI":"10.1016\/j.jmb.2010.02.043"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10613-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:03:02Z","timestamp":1784116982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10613-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":51,"journal-issue":{"issue":"8123","published-print":{"date-parts":[[2026,7,16]]}},"alternative-id":["10613"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10613-5","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.Y., L.W.\u00a0(Degron Therapeutics), C.X., I-C.L., C.G., X.Q., H.D. and H.S. are current employees and shareholders of Degron Therapeutics. Y.C. is a shareholder and consultant of Degron Therapeutics, and receives research funding from Degron Therapeutics. Z.Y., H.S., C.G. and H.D. have a patent related to this work: WO2024114639A, titled \u2018Compounds for modulating HuR (\n                      ELAVL1\n                      )\u2019; these authors declare no other competing interests. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}